Current best evidence for clinical care (more info)
The therapeutic options for COVID-19 patients are currently limited, but numerous randomized controlled trials are being completed, and many are on the way. For COVID-19 patients in low- and middle-income countries (LMICs), we recommend against using remdesivir outside of a clinical trial. We recommend against using hydroxychloroquine ± azithromycin or lopinavir-ritonavir. We suggest empiric antimicrobial treatment for likely coinfecting pathogens if an alternative infectious cause is likely. We suggest close monitoring without additional empiric antimicrobials if there are no clinical or laboratory signs of other infections. We recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation. We recommend against using dexamethasone in patients with COVID-19 who do not require supplemental oxygen. We recommend using alternate equivalent doses of steroids in the event that dexamethasone is unavailable. We also recommend using low-dose corticosteroids in patients with refractory shock requiring vasopressor support. We recommend against the use of convalescent plasma and interleukin-6 inhibitors, such as tocilizumab, for the treatment of COVID-19 in LMICs outside of clinical trials.
|Discipline / Specialty Area||Score|
|Tropical and Travel Medicine||
There has been a lot of misinformation about therapeutics for Covid-19. This lays out the information in a reasonable fashion.
No words for the use of low molecular weight heparin!
This is a good review of the treatment options in COVID-19. Awfully, they don't cover non-pharmacologic treatment.
This article is highly relevant and gives the much needed evidence based guidelines in managing patients with COVID-19.
Most of this is already known. This is useful information to argue against enthusiastic prescriptions by colleagues.